Skip to main content
LLY
NYSE Life Sciences

FDA Grants Full Approval to Lilly's Inluriyo for ESR1-Mutated Breast Cancer

Tom Rudovsky · Reported by Benzinga
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,171.335
Mkt Cap
$1.103T
52W Low
$712.05
52W High
$1,292.65
52W Position info
65% above low
Off High info
9.4% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

LLY sits 65% above its 52-week low of $712.05.

Summary

The FDA granted full approval to Inluriyo (imlunestrant) in combination with Verzenio for pretreated ER+/HER2- ESR1-mutated advanced breast cancer. The approval is based on the Phase 3 EMBER-3 trial, where the combination doubled median progression-free survival to 11.1 months versus 5.5 months for Inluriyo alone. This expands Lilly's oncology franchise and leverages the established Verzenio brand. TD Securities projects Inluriyo sales of $290 million in 2026, rising to $1.05 billion by 2032. The adjuvant setting (EMBER-4 trial) represents a larger opportunity, with initial results expected in 2027.

At the time of this announcement, LLY was trading at $1,171.34 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $712.05 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Oct 29, 2026, 3:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1,368.10
Real-time Price: $1,383.29 info
Change: +$15.19 (+1%) info
Market Cap: $1.293T info
LLY
Oct 29, 2026, 12:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,370.30
Real-time Price: $1,383.29 info
Change: +$12.99 (+0.95%) info
Market Cap: $1.293T info
LLY
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1,363.50
Real-time Price: $1,383.29 info
Change: +$19.79 (+1%) info
Market Cap: $1.293T info
LLY
Oct 29, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1,344.00
Real-time Price: $1,383.29 info
Change: +$39.29 (+3%) info
Market Cap: $1.293T info
LLY
Oct 29, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $1,345.00
Real-time Price: $1,383.29 info
Change: +$38.29 (+3%) info
Market Cap: $1.293T info